Edgen Stock·Nov 24 2025, 13:01返回
返回
諾和諾德口服索馬魯肽在阿茲海默症試驗中失敗，股價下跌10%
Edgen Stock·Nov 24 2025, 13:01
[1] 諾和諾德稱阿茲海默症藥物試驗未能達到主要目標 (https://www.reuters.com/business/healthcare-p ...)[2] 諾和諾德股價暴跌，因Ozempic口服藥在阿茲海默症試驗中失敗... (https://www.wsj.com/health/pharma/novo-nordis ...)[3] 諾和諾德稱阿茲海默症藥物試驗失敗，股價受重創 (https://www.investing.com/news/stock-market-n ...)